Actively Recruiting
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
Led by University of Virginia · Updated on 2026-05-06
80
Participants Needed
1
Research Sites
338 weeks
Total Duration
On this page
Sponsors
U
University of Virginia
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume, improves vascular function of the conduit vessels, and enhances insulin's metabolic action in humans with Metabolic Syndrome. Subjects will be randomized to one of the 4 groups: control, exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 24 weeks of intervention.
CONDITIONS
Official Title
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 21 to 60 years
- Body mass index (BMI) greater than 25 and up to 35 kg/m2 and weight stable (less than 5 kg change in past 6 months)
- Meet at least 3 of 5 Metabolic Syndrome criteria including increased waist circumference, elevated triglycerides, reduced HDL-cholesterol, high blood pressure, or elevated fasting glucose
- Stable doses for at least 3 months if using certain medications such as ACE inhibitors, ARBs, statins, beta blockers, calcium channel blockers, or alpha-adrenergic antagonists
You will not qualify if you...
- Diagnosis of any type of diabetes or history of diabetes medication use
- Engaging in moderate or high intensity exercise more than 20 minutes twice per week recently
- Current smokers or those who quit smoking less than 5 years ago
- High triglycerides over 400 mg/dl or cholesterol over 260 mg/dl
- Blood pressure over 160/90 mmHg
- History of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, endocrine diseases, or cancer
- Pregnant or nursing women
- Contraindications to exercise training
- Allergy to perflutren
- Prior use of liraglutide
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Virginia
Charlottesville, Virginia, United States, 22906
Actively Recruiting
Research Team
L
Lee Hartline, MEd
CONTACT
L
Linda Jahn, MEd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here